Please assess the completion status of the following clinical trial:

Trial Title: Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Haemophilia A~* Body Mass Index (BMI) below 35 kg/m2~* History of a minimum 150 exposure days (EDs) to FVIII products (prophylaxis/prevention/surgery/on-demand)~Exclusion Criteria:~* Any history of FVIII inhibitors~* Surgery planned to occur during the trial~* Platelet count less than 50,000 platelets/microlitre (assessed by laboratory)~* Congenital or acquired coagulation disorders other than haemophilia A

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: EXPERIMENTAL): None
- C (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).